Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals-Reference-Cited by-同舟云学术

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals

Published:2023-05-05 Issue:7 Volume:38 Page:1236-1252
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Movement Disorders

Author:

Jost Stefanie T.¹^ORCID,Kaldenbach Marie‐Ann¹,Antonini Angelo²^ORCID,Martinez‐Martin Pablo³^ORCID,Timmermann Lars⁴,Odin Per⁵⁶,Katzenschlager Regina⁷,Borgohain Rupam⁸,Fasano Alfonso⁹¹⁰¹¹¹²^ORCID,Stocchi Fabrizio¹³,Hattori Nobutaka¹⁴,Kukkle Prashanth Lingappa¹⁵¹⁶^ORCID,Rodríguez‐Violante Mayela¹⁷¹⁸^ORCID,Falup‐Pecurariu Cristian¹⁹²⁰,Schade Sebastian²¹^ORCID,Petry‐Schmelzer Jan Niklas¹^ORCID,Metta Vinod²²²³,Weintraub Daniel²⁴²⁵^ORCID,Deuschl Guenther²⁶^ORCID,Espay Alberto J.²⁷^ORCID,Tan Eng‐King²⁸²⁹,Bhidayasiri Roongroj³⁰³¹^ORCID,Fung Victor S.C.³²^ORCID,Cardoso Francisco³³^ORCID,Trenkwalder Claudia³⁴³⁵,Jenner Peter³⁶,Ray Chaudhuri K.²²²³³⁷,Dafsari Haidar S.¹,

Affiliation:

1. Department of Neurology Faculty of Medicine and University Hospital Cologne, University of Cologne Cologne Germany

2. Parkinson and Movement Disorders Unit, Department of Neurosciences (DNS) University of Padua Padova Italy

3. Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED) Carlos III Institute of Health Madrid Spain

4. Department of Neurology University Hospital Giessen and Marburg Marburg Germany

5. Division of Neurology Lund University Lund Sweden

6. Department of Neurology Skåne University Hospital Lund Sweden

7. Department of Neurology Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders at Klinik Donaustadt Vienna Austria

8. Department of Neurology Nizam's Institute of Medical Sciences Hyderabad India

9. Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic Toronto Western Hospital–University Health Network (UHN) Toronto Ontario Canada

10. Division of Neurology University of Toronto Toronto Ontario Canada

11. Krembil Research Institute Toronto Ontario Canada

12. Department of Parkinson's Disease & Movement Disorders Rehabilitation Moriggia‐Pelascini Hospital–Gravedona ed Uniti Como Italy

13. University and Institute for Research and Medical Care IRCCS San Raffaele Rome Italy

14. Department of Neurology Juntendo University Graduate School of Medicine Tokyo Japan

15. Center for Parkinson's Disease and Movement Disorders Manipal Hospital Bangalore India

16. Parkinson's Disease and Movement Disorders Clinic Bangalore India

17. Insituto Nacional de Neurologia y Neurocirugia Movement Disorders Clinic Mexico City Mexico

18. Movement Disorder Clinic National Institute of Neurology and Neurosurgery Mexico City Mexico

19. Department of Neurology, Faculty of Medicine Transilvania University of Brașov Brașov Romania

20. Department of Neurology County Emergency Clinic Hospital Brașov Romania

21. Department of Clinical Neurophysiology University Medical Center Göttingen Göttingen Germany

22. Parkinson Foundation International Centre of Excellence King's College Hospital London United Kingdom

23. Institute of Psychiatry, Psychology and Neuroscience King's College London London United Kingdom

24. Departments of Psychiatry and Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

25. Parkinson's Disease Research, Education and Clinical Center (PADRECC) Corporal Michael J. Crescenz Veterans Affairs Medical Center Philadelphia Pennsylvania USA

26. Department of Neurology University Hospital Schleswig‐Holstein (UKSH), Christian‐Albrechts‐University Kiel Kiel Germany

27. University of Cincinnati Gardner Neuroscience Institute, Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology University of Cincinnati Cincinnati Ohio USA

28. Department of Neurology, National Neuroscience Institute Singapore General Hospital Singapore Singapore

29. Neuroscience and Behavioral Disorders (NBD) Department Duke–NUS Medical School Singapore Singapore

30. Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital Bangkok Thailand

31. The Academy of Science The Royal Society of Thailand Bangkok Thailand

32. Movement Disorder Unit, Department of Neurology Westmead Hospital Westmead Australia

33. Movement Disorders Unit, Internal Medicine Department Universidade Federal de Minas Gerais Belo Horizonte Brazil

34. Paracelsus‐Elena‐Klinik Kassel Germany

35. Department of Neurosurgery University Medical Center Göttingen Göttingen Germany

36. Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine King's College London London United Kingdom

37. NIHR Mental Health Biomedical Research Centre and Dementia Biomedical Research Unit South London and Maudsley NHS Foundation Trust and King's College London London United Kingdom

Abstract

AbstractBackgroundTo compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.ObjectivesTo update LED conversion formulae based on a systematic review.MethodsThe MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.ResultsThe systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.ConclusionsThe LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non‐pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference76 articles.

1. Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features

2. Systematic review of levodopa dose equivalency reporting in Parkinson's disease

3. Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent‐Wide Survey

4. Average annual cost of Parkinson’s disease in São Paulo, Brazil, with a focus on disease-related motor symptoms

5. Prescription pattern and awareness of disease and treatment in patients of Parkinson's disease

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune landscape of the enteric nervous system differentiates Parkinson's disease patients from controls: The PADUA-CESNE cohort;Neurobiology of Disease;2024-10

2. Dynamic cerebellar and sensorimotor network compensation in tremor-dominated Parkinson's disease;Neurobiology of Disease;2024-10

3. Do Acoustic Characteristics of Dysarthria in People With Parkinson's Disease Differ Across Languages?;Journal of Speech, Language, and Hearing Research;2024-09-12

4. Case report: Improvement of gait with adaptive deep brain stimulation in a patient with Parkinson’s disease;Frontiers in Bioengineering and Biotechnology;2024-09-11

5. Therapeutic drug monitoring in Parkinson’s disease;Journal of Neural Transmission;2024-09-03